AbbVie Sets Out Expectations For 2024 Humira Competition

Offers Overview Of Anticipated Impact From Adalimumab Biosimilars In The Year Ahead

 
• By Dave Wallace
  
arrow pointing to the year 2024 on a raised metal dial
AbbVie has given clearer indications on how it sees Humira competition playing out in 2024

More from Biosimilars

More from Products